Lonza, SRU Biosystems

Lonza has developed new Amaxa Nucleofector kits for the transfection of primary mouse B cells, from single reactions up to 96-well transfections, the company announced this week.
Results of up to 74 percent transfection efficiency for stimulated mouse B cells and a viability of 59 percent for human hepatocytes 120 hours post nucleofection have been achieved, the company said.
New Amaxa Nucleofector kits are also available for the transfection of human hepatocytes and human chondrocytes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.